logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
P

Philip J. Mease

providence swedish medical center and university of washington school of medicine

117H-index
1.1KPaper Count
7.6WCitation Count
Published Papers 404
Publication Date
logo
Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial
errArthritis & Rheumatology
IF10.9
err2026-07-28
err0
errOAAI
errPhilip J. Mease; Vinod Chandran; April W. Armstrong; Ricardo Blanco; Alexis Ogdie; Evan L. Siegel; Alice B. Gottlieb; Xiaofeng Zeng; Diamant Thaçi; Mitsumasa Kishimoto; Hendrik Schulze-Koops; Alan Kivitz; Eva Dokoupilová; Akimichi Morita; Eric M. Ruderman; Michael Plewinski; Kejia Wang; Caroline Sardinas; Eleni Vritzali; John Vaile; Atul Deodhar
errShare
errSave
Effects of Guselkumab on Structural Damage Progression in Patients with Active Psoriatic Arthritis
errAdvances in Therapy
IF4
err2026-05-05
err0
errOAAI
errChristopher T. Ritchlin; Laura C. Coates; Philip J. Mease; Désirée van der Heijde; Proton Rahman
errShare
errSave
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial
errArthritis & Rheumatology
IF10.9
err2026-03-28
err0
errOAAI
errJoseph F. Merola; Philip Mease; Alan Kivitz; Naveed Sattar; Laura C. Coates; Daniel Aletaha; Cynthia E. Kartman; Peter Fischer; Luna Sun; Píndaro Martínez-Osuna; Andris Kronbergs; Purvi Prajapati; Anabela Cardoso; Mark C. Genovese; Alexis Ogdie
errShare
errSave
Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From the Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept AFFINITY Study
errArthritis & Rheumatology
IF10.9
err2026-03-25
err0
PREAI
errJose U Scher MD; Iain B McInnes MD, PhD; Enrique R Soriano MD, MSc; Joseph F Merola MD, MMSc; Paul Bird MD, PhD; Vinod Chandran MD, PhD; Edaire Cheng MD; Elena Reynoso MD; Warner Chen PhD; Maoji Li MS; Lianne S Gensler MD; Philip J Mease MD; Christopher T Ritchlin MD, MPH
errShare
errSave
Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of the Phase 3, Randomized, Placebo-Controlled SOLSTICE Study
errArthritis & Rheumatology
IF10.9
err2026-02-11
err0
errOAAI
errAlexis Ogdie MD; Joseph F Merola MD, MMSc, FAAD, FACR; Philip J Mease MD; Christopher T Ritchlin MD, MPH; Jose U Scher MD; Kimberly Parnell Lafferty PharmD, MBA; Daphne Chan PhD; Soumya D Chakravarty MD, PhD; Wayne Langholff PhD; Yanli Wang MS; Jie Shao PhD; Yevgeniy Krol MBA; Alice B Gottlieb MD, PhD
errShare
errSave
Quantifying Disease Activity Despite Treatment with Tumor Necrosis Factor Inhibitors Among Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Real-World Results from the PPD CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
errRheumatology and Therapy
IF2.9
err2026-01-07
err0
errOAAI
errPhilip Mease; Xiaolan Ye; Christopher D. Saffore; Bhumik Parikh; Sandra Ciecinski; Taylor Blachley; Melissa Eliot; Nicole Middaugh; Alexis Ogdie
errShare
errSave
Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials
errRheumatology and Therapy
IF2.9
err2025-12-15
err0
errOAAI
errDafna D. Gladman; Lihi Eder; Carlo Selmi; Philip J. Mease; Alexis Ogdie; Karissa Lozenski; Elizabeth Adamson; Mohamed Sharaf; Emmanouil Rampakakis; Laura Pina Vegas; Laura C. Coates
errShare
errSave
Effectiveness of Tofacitinib in Patients with Psoriatic Arthritis Initiating Monotherapy Versus Combination Therapy: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
errRheumatology and Therapy
IF2.9
err2025-12-04
err0
errOAAI
errAlexis Ogdie; Nicole Middaugh; Taylor Blachley; Tran Bourgeois; You-Li Ling; Rajiv Mundayat; Lara Fallon; Karim R. Masri; Philip J. Mease
errShare
errSave
GRAPPA 2024 Annual Meeting: An Update on Major Project Milestones
errJOURNAL OF RHEUMATOLOGY
IF3.4
err2025-12-01
err1
PREAI
errColaco, Keith; Eder, Lihi; Grieb, Suzanne M.; Leung, Ying Ying; Lubrano, Ennio; Mease, Philip J.; Perez-Chada, Lourdes M.; Poddubnyy, Denis; Soriano, Enrique R.; Chandran, Vinod
errShare
errSave
GRAPPA 2024: Innovations in Education Workshop
errJOURNAL OF RHEUMATOLOGY
IF3.4
err2025-12-01
err1
PREAI
errAyan, Gizem; Husni, M. Elaine; Mathew, Ashish J.; Mcinnes, Iain B.; Mease, Philip J.
errShare
errSave
What Clinicians Need to Know About Glucagon-like Peptide 1 Agonists
errJOURNAL OF RHEUMATOLOGY
IF3.4
err2025-12-01
err1
PREAI
errda Silva, Dimitri Luz Felipe; Singla, Shikha; Mease, Philip J.
errShare
errSave
GRAPPA 2024: Key Project Advances
errJOURNAL OF RHEUMATOLOGY
IF3.4
err2025-12-01
err1
PREAI
errAyan, Gizem; Helliwell, Philip S.; Lindsay, Christine A.; Mease, Philip J.; O'sullivan, Denis; Pennington, Stephen R.; Proft, Fabian; FitzGerald, Oliver
errShare
errSave
Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative
errNature Reviews Rheumatology
IF32.7
err2025-11-27
err0
PREAI
errFabian Proft; Andre L. Ribeiro; Shikha Singla; Vinod Chandran; Wilson Liao; Christine Lindsay; Enrique R. Soriano; Tina Bhutani; Atul Deodhar; Kurt de Vlam; Lihi Eder; Mitsumasa Kishimoto; Ying Ying Leung; Ennio Lubrano; Dennis McGonagle; Denis Poddubnyy; Laura Savage; Filip Van den Bosch; Philip Mease
errShare
errSave
Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors
errAdvances in Therapy
IF4
err2025-11-21
err0
errOAAI
errPhilip J. Mease; Jessica A. Walsh; Timothy P. Fitzgerald; Soumya D. Chakravarty; Elizabeth Adamson; Bruno Emond; Carmine Rossi; Samuel Schwartzbein; Kana Yokoji; Yuxi Wang; Patrick Lefebvre; Dominic Pilon; Shikha Singla; Joseph F. Merola
errShare
errSave
On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors
errRheumatology and Therapy
IF2.9
err2025-11-14
err0
errOAAI
errPhilip J. Mease; Jessica A. Walsh; Timothy P. Fitzgerald; Soumya D. Chakravarty; Elizabeth Adamson; Bruno Emond; Carmine Rossi; Samuel Schwartzbein; Kana Yokoji; Yuxi Wang; Patrick Lefebvre; Dominic Pilon; Shikha Singla; Joseph F. Merola
errShare
errSave
Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial
errNature Medicine
IF50
err2025-10-06
err0
errOAAI
errIain B. McInnes; Laura C. Coates; Philip J. Mease; Alexis Ogdie; Arthur Kavanaugh; Lihi Eder; Georg Schett; Alan Kivitz; Dennis McGonagle; Nuala Brennan; Alex Godwood; Eva Cullen; Kristian Reich; Christopher T. Ritchlin; Joseph F. Merola
errShare
errSave
Relationship of radiographic progression status to low disease activity in patients with PsA receiving secukinumab treatment for 2 years
errRHEUMATOLOGY
IF4.4
err2025-10-01
err0
PREAI
errMease, Philip J.; Coates, Laura C.; Gaillez, Corine; Shew, Alexis; Bao, Weibin; Ritchlin, Christopher T.
errShare
errSave
Efficacy and Safety of Deucravacitinib, a Selective, Allosteric TYK2 Inhibitor, by Baseline DMARD Use in a Phase 2 Psoriatic Arthritis Study: A Post Hoc Analysis
errRheumatology and Therapy
IF2.9
err2025-07-05
err0
errOAAI
errAtul Deodhar; Miroslawa Nowak; June Y. Ye; Tom Lehman; Subhashis Banerjee; Philip J. Mease
errShare
errSave
Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
errRHEUMATOLOGY AND THERAPY
IF2.9
err2025-05-10
err0
errOAAI
errPhilip J. Mease; Joseph F. Merola; Yoshiya Tanaka; Laure Gossec; Iain B. McInnes; Christopher T. Ritchlin; Robert B. M. Landewé; Akihiko Asahina; Barbara Ink; Andrea Heinrichs; Rajan Bajracharya; Vishvesh Shende; Jason Coarse; Laura C. Coates
errShare
errSave
Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies (vol 11, pg 1363, 2024)
errRHEUMATOLOGY AND THERAPY
IF2.9
err2025-05-05
err0
errOAAI
errPhilip J. Mease; Joseph F. Merola; Yoshiya Tanaka; Laure Gossec; Iain B. McInnes; Christopher T. Ritchlin; Robert B. M. Landewé; Akihiko Asahina; Barbara Ink; Andrea Heinrichs; Rajan Bajracharya; Vishvesh Shende; Jason Coarse; Laura C. Coates
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
L
Leroy Hood
H-index: 166 · Papers: 1.0K
D
David T. Felson
H-index: 162 · Papers: 1.2K
M
Markus M. Nöthen
H-index: 161 · Papers: 2.0K
P
Paul Emery
H-index: 158 · Papers: 1.6K
A
Antoni Ribas
H-index: 158 · Papers: 1.7K
View more